Cytokinetics Inc. (CYTK)

Cytokinetics' Myqorzo gains FDA approval, driving stock to a 52-week high amidst analyst optimism, though market sentiment and competition remain factors.

About Cytokinetics Inc.

Cytokinetics Inc. is a biopharmaceutical company focused on the development of muscle activators.
Cytokinetics Inc. uses the ticker $CYTK for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

• Cytokinetics Inc. (CYTK) mentions hit [---] which is 112% higher than it's daily average.
• Cytokinetics Inc. (CYTK) creators is up 17.24% from the previous week.
• Cytokinetics Inc. (CYTK) mentions is up 17.54% from the previous week.
• Cytokinetics Inc. (CYTK) posts created is up 340% from the previous week.

Price: $66.30

Price 24-Hour Time-Series Raw Data
The stock price has surged to a 52-week high, driven by the FDA approval of Myqorzo and positive analyst sentiment, despite some valuation concerns and general market negativity.

24-Hour: 1.18% 7-Day: 6.68% 30-Day: 5.88%

1-Year High: $68.20 on 2025-11-26
1-Year Low: $29.80 on 2025-05-15

AltRank: [---]

AltRank 24-Hour Time-Series Raw Data
Cytokinetics Inc. (CYTK) is currently AltRank #537 based on combined combined social and market metrics Daily Average: [---]
[--] Week: [---] [----]
[--] Month: [---] +149
[--] Months: [---] [----]
[--] Year: [---] +256
1-Year High: [-----] on 2025-06-29
1-Year Low: [--] on 2025-09-02

Galaxy Score: [-----]

Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] [---]
[--] Months: [--] +4
[--] Year: [--] [---]
1-Year High: [--] on 2025-04-24
1-Year Low: [--] on 2025-08-01

Engagements: [-----] (24h)

Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [------] -42%
[--] Month: [-------] -76%
[--] Months: [---------] +74%
[--] Year: [---------] +8.70%
1-Year High: [-------] on 2025-09-02
1-Year Low: [---] on 2026-02-08

Engagements by network (24h): YouTube: [--] X: [-----] Reddit: [--] TikTok: [--] News: [-----]

Mentions: [---] (24h)

Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
[--] Week: [---] +18%
[--] Month: [-----] +5%
[--] Months: [-----] +48%
[--] Year: [-----] +3.40%
1-Year High: [---] on 2025-09-03
1-Year Low: [--] on 2025-06-13

Mentions by network (24h): YouTube: [--] X: [---] Reddit: [--] TikTok: [--] News: [--]

Creators: [---] (24h)

Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning Cytokinetics Inc. (CYTK) in the last [--] hours which is up 68% from [--] in the previous [--] hours Daily Average: [--]
[--] Week: [---] +17%
[--] Month: [---] +11%
[--] Months: [-----] +1.40%
[--] Year: [-----] +75%
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2025-05-24

The most influential creators that mention Cytokinetics Inc. in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@Quantumup1	[--]	[-----]	[--]	[---]
@JaksonMika78723	[--]	[--]	[--]	[---]
@Stock_Analysis3	[--]	[---]	[--]	[--]
@Emily56392	[--]	[--]	[--]	[--]
@semodough	[--]	[------]	[--]	[--]
@BiswasMisi60052	[--]	[--]	[--]	[--]
@_le_Lounge	[--]	[-----]	[--]	[--]
@WolfOfPathogens	[--]	[--]	[--]	[--]
@PersimmonTI	[--]	[------]	[--]	[--]
@tajSalter85175	[--]	[--]	[--]	[--]

View More

Sentiment: 49%

Sentiment 24-Hour Time-Series Raw Data
Current Value: 49%
Daily Average: 73%
[--] Week: 29% -51%
[--] Month: 30% -30%
[--] Months: 30% -47%
[--] Year: 30% -44%
1-Year High: 100% on 2025-04-22
1-Year Low: 26% on 2025-12-07

Most Supportive Themes:

• FDA Approval of Myqorzo: (70%) Cytokinetics' aficamten (Myqorzo) has received FDA approval for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking a significant milestone for the company.
• Myqorzo's Differentiated Profile: (20%) Market analysis suggests Myqorzo's label and REMS program are differentiated from competitors like Camzyos, potentially offering advantages in administration and monitoring.
• Positive Analyst Sentiment and Price Targets: (10%) Analysts have reiterated outperform ratings and increased price targets for CYTK, citing the FDA approval and Myqorzo's strong market potential.

Most Critical Themes:

• General Market Sentiment: (50%) Despite positive company-specific developments, general negative market sentiment is currently influencing commentary about Cytokinetics Inc. (CYTK).
• Competition from Camzyos: (30%) While Myqorzo shows promise, it faces competition from an entrenched competitor, Camzyos, and its market adoption will be closely watched.
• Valuation Concerns: (20%) Some users express difficulty in justifying the current valuation for CYTK, despite the positive news, indicating potential overvaluation concerns.

Social Dominance: 0.02%

Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.02%
Daily Average: 0.018%
[--] Week: 2.10% +2.10%
[--] Month: 0.025% +0.013%
[--] Months: 0.025% +0.013%
[--] Year: 0.025% +0.0028%
1-Year High: 0.079% on 2025-09-03
1-Year Low: 0.0059% on 2025-10-24

Market Dominance: 0.00918%

Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00918%
Daily Average: 0%
1-Year High: 0.021% on 2025-03-31
1-Year Low: 0.00491% on 2025-05-15

Market Cap: $8,101,274,196

Market Cap 24-Hour Time-Series Raw Data
Current Value: $8,101,274,196
Daily Average: $5,816,589,841
[--] Week: $8,101,274,196 +4.60%
[--] Month: $8,101,274,196 +5.90%
[--] Months: $8,101,274,196 +81%
[--] Year: $8,101,274,196 +49%
1-Year High: $8,332,354,911 on 2025-11-26
1-Year Low: $3,563,710,423 on 2025-05-15

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing